Periodic Reporting for period 1 - Redwave (Redwave: the future of blood pressure measurement)
Période du rapport: 2018-06-01 au 2018-11-30
Redwave Medical is a producer of innovative medical algorithms for diagnostic devices in the field of heart and artery diseases. We are focused on central (aortic) blood pressure (cBP) and pulse wave analysis. The project Antares (formerly “Redwave”) is a new oscillometric solution which measures cBP, by combining any regular BP monitor with our new algorithm Antares, which uses the oscillating curves of the BP monitor as input signals without changes in the pumping protocol or in the device hardware. The algorithm is based on the advanced development of Pulse Wave Analysis, a method already used in clinics and specialized practices. Our solution is matching the requirements in robustness and accuracy of the non-controlled environment as it typically exists in homecare measurements. For this reason, it enables the measurement of cBP with home care devices for the first time.
Our main objectives from the grant agreement were to validate and refine our business model, to perform a technology study to assess the technical viability, to complete the market study for identification of potential customers segments in Europe and to plan our communication goals.
We have addressed all four topics by our activities, leading to a completed and improved business plan. Most important, we have reached the first license agreement with a customer and a detailed roadmap to market entry – a clear proof of our business model. Furthermore, technological feasibility has been proven and the algorithm is currently validated in an invasive trial. Additionally, we have established a quality management system, qualifying us as a supplier for medical device manufacturers, and we have developed and follow our patent strategy. We also have completed a market study, with a focus on general market trends, customer segmentation in Europe and competitor analysis. Based on this data, we have planned our upcoming R&D actions to develop the product portfolio and our marketing and communication strategy.
We have addressed all four topics by our activities, leading to a completed and improved business plan. Most important, we have reached the first license agreement with a customer and a detailed roadmap to market entry – a clear proof of our business model. Furthermore, technological feasibility has been proven and the algorithm is currently validated in an invasive trial. Additionally, we have established a quality management system, qualifying us as a supplier for medical device manufacturers, and we have developed and follow our patent strategy. We also have completed a market study, with a focus on general market trends, customer segmentation in Europe and competitor analysis. Based on this data, we have planned our upcoming R&D actions to develop the product portfolio and our marketing and communication strategy.
All in all, as OEM-Software our algorithm will revolutionize hypertension self-monitoring and therapy by the patients – about 85 million people in Europe. The central blood pressure cBP directly affects heart and brain and therefore is directly responsible for heart attacks and strokes, but it differs from the currently measured blood pressure in the arm. By easy and regular measurement of cBP at home, a patient can sustainably reduce the risk and improve hypertension therapy.